SCHEMBL118322

SCHEMBL118322

CCOC(COc1ccc(OC)cc1C=O)OCC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.54
RAB9A P51151 1/20 0.54
ALDH1A1 P00352 6/20 0.46
ERN1 O75460 2/20 0.45
TUBB1 Q9H4B7 1/20 0.45
TRIM24 O15164 1/20 0.42
TYR P14679 1/20 0.42
TRIM33 Q9UPN9 1/20 0.42
BACE1 P56817 1/20 0.40
JUN P05412 1/20 0.38
NFKB1 P19838 1/20 0.38
NFE2L2 Q16236 2/20 0.38
CYP1A2 P05177 3/20 0.38
CYP1A1 P04798 1/20 0.38
CYP1B1 Q16678 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
CYP2C19 P33261 2/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MAPT P10636 1/20 0.38
POLB P06746 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1400196 0.85 KDM4E (0.51) KDM4ERAB9AALDH1A1ERN1TUBB1
SCHEMBL20488634 0.84 KDM4E (0.59) KDM4ERAB9AALDH1A1ERN1TUBB1
SCHEMBL28586233 0.83 RAB9A (0.45) KDM4ERAB9AALDH1A1ERN1TUBB1
SCHEMBL11886577 0.83 SRC (0.38) KDM4ERAB9AALDH1A1ERN1SMN1; SMN2
SCHEMBL117197 0.82 ALDH1A1 (0.46) KDM4ERAB9AALDH1A1SMN1; SMN2MAPT
SCHEMBL120322 0.82 HPGD (0.47) KDM4ERAB9AALDH1A1ERN1SMN1; SMN2
SCHEMBL5046907 0.80 KDM4E (0.51) KDM4ERAB9AALDH1A1ERN1TUBB1
SCHEMBL15068012 0.80 CA12 (0.39) KDM4ERAB9AALDH1A1SMN1; SMN2L3MBTL1
SCHEMBL119328 0.80 ALDH1A1 (0.43) KDM4ERAB9AALDH1A1ERN1TUBB1
SCHEMBL3221472 0.79 BACE1 (0.58) KDM4ERAB9AALDH1A1ERN1TUBB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4691558-A2 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS University Court of The University of Dundee (GB) 2026-02-11 EP disclosed
US-20250295789-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2025-09-25 US disclosed
EP-2857018-B1 Treatment or prophylaxis of proliferative conditions UNIV COURT OF THE UNIV OF DUNDEE (GB) 2025-09-03 EP disclosed
US-20220031852-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2022-02-03 US disclosed
US-20220031852-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2022-02-03 US disclosed
US-20200360521-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2020-11-19 US disclosed
US-9919060-B2 Treatment or prophylaxis of proliferative conditions UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2018-03-20 US disclosed
US-9919060-B2 Treatment or prophylaxis of proliferative conditions UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2018-03-20 US disclosed
US-20170368188-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2017-12-28 US disclosed
EP-2857018-A1 Treatment or prophylaxis of proliferative conditions University Court of The University of Dundee (GB) 2015-04-08 EP disclosed
US-8283340-B2 Treatment or prophylaxis of proliferative conditions The University of the University of Dundee (GB) 2012-10-09 US disclosed
US-8283340-B2 Treatment or prophylaxis of proliferative conditions The University of the University of Dundee (GB) 2012-10-09 US disclosed
US-20120190639-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2012-07-26 US disclosed
US-20120190639-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2012-07-26 US disclosed
EP-2424524-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS University Court of The University of Dundee (GB) 2012-03-07 EP disclosed
US-20100305070-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2010-12-02 US disclosed
US-20100305070-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2010-12-02 US disclosed
US-20100305070-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2010-12-02 US disclosed
WO-2010125350-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2010-11-04 WO disclosed
WO-2010125350-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2010-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305070-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS BRCA1, CYP1B1, UGT1A1 KDM4E 4346/4885RAB9A 2833/4885ALDH1A1 35/4885
US-20200360521-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS CYP1B1, UGT1A1, CYP1A1 KDM4E 3646/4885RAB9A 3268/4885ALDH1A1 55/4885
US-20120190639-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS CYP1B1, UGT1A1, CYP1A1 KDM4E 3646/4885RAB9A 3268/4885ALDH1A1 55/4885
US-20220031852-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS CYP1B1, UGT1A1, CYP1A1 KDM4E 3646/4885RAB9A 3268/4885ALDH1A1 55/4885
US-20250295789-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS CYP1B1, BRCA1, UGT1A1 KDM4E 3589/4885RAB9A 3403/4885ALDH1A1 32/4885
US-20170368188-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS CYP1B1, UGT1A1, CYP1A1 KDM4E 3979/4885RAB9A 3673/4885ALDH1A1 61/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.